Stewart Thomas Carlton sold $24K of CGC

Stewart Thomas Carlton (See Remarks) sold 25,755 shares of Canopy Growth Corp (CGC) at $0.93 on 2026-09-17.

Original reporting
SEC EDGAR · Stewart Thomas Carlton
Published Sep 17, 2026, 10:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGC
Neutral
high confidence
Mentioned
$CGC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

The sale is minor and unlikely to affect CGC's stock price.

02

Market read

Limited relevance; routine insider transaction.

03

What to watch

Potential upcoming corporate actions not disclosed; monitor future filings.

Relevance 3/10Novelty 4/10Timing: same day filing

Background

Form 4 filings disclose insider transactions; traders watch for material sales.

Company-level read

Ticker impact

$CGCNeutralHigh confidence
Context

Officer Stewart Thomas Carlton sold 25,755 shares of Canopy Growth Corp for $23,952 on 2026-09-17.

Expected impact

minimal impact, possible slight downward pressure

Evidence & confidence

The transaction size (~$24k) is trivial relative to market cap and typical trading volume.

Market effects

None significant for cannabis sector.

No regional effect.

No global relevance.

Counterpoint

Insider sale could signal concerns, but size is too small to be meaningful.

Key entities

  • Stewart Thomas Carlton

    Officer of Canopy Growth Corp who sold shares.

  • Canopy Growth Corp

    Canadian cannabis producer listed on US exchanges under ticker CGC.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.